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ECONOMIC AND OUTCOMES ISSUES 
OF CANCER
PCD1
DIRECT AND INDIRECT COSTS OF 
CHEMOTHERAPY-INDUCED TOXICITY
Calhoun E, Fishman D, Roland P, Lurain J, Bennett C
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OBJECTIVE: Chemotherapy-induced toxicities (CIT)
may have a significant impact on overall healthcare costs;
however, there is limited research on the total costs asso-
ciated with CIT, particularly indirect costs. The objective
of this prospective study is to assess the cost of neuro-
logic and hematologic toxicities in women with breast
and gynecologic cancers. 
METHODS: Women experiencing CIT completed ques-
tionnaires that assessed healthcare utilization and patient
and caregiver productivity loss. Direct medical costs were
based on hospital cost-accounting data and indirect costs
were based on Labor Force, Employment, and Earnings
data. 
RESULTS: The average time in the study for hematotoxic-
ity was 2.9 months and 5.5 months for the neurotoxicity
group. The mean age for women in the study was 59.5
years with an average household income of $44,702. The
mean direct medical costs for hematotoxicity were $2172
(sd  $2818, range  $0–$9500) and $460 (sd  $1920,
range  $0–$3500) for neurotoxicity. Patient-related indi-
rect costs for hematotoxicity averaged $2778 (sd 
$2627, range  $291–$8791) in lost wages compared to
$12,460 (sd  $8370, range  $169–$23,976) for neuro-
toxicity. Additionally, non-paid caregivers were needed
38% of the time for women with hematotoxicity and
missed work 43.7% of the time for an average of 2.5
hours/week. While women with neurotoxicity required
more help from informal caregivers (53.7%) incurring an
average of 4 hours per week of lost wages. Paid workers
were needed 44.5% (mean  6.75 hours/week) for hema-
totoxicity and 26.8% (mean  3.7 hours/week) for neuro-
toxicity. 
CONCLUSIONS: Chemotherapy-induced hemato- and
neurotoxicities have significant direct and indirect costs.
Neurotoxicity appears to result in a disproportionate
amount of indirect costs due in part to longer duration of
neurotoxicity-related morbidities. Future research on the
costs of CIT should include an assessment of the impact
of indirect costs.
PCD2
COSTS ASSOCIATED WITH 
CHEMOTHERAPY-INDUCED TOXICITIES:
A REVIEW OF THE LITERATURE
Jackson S1, Peeples P1, Hanson-Divers C2
1Alza Corporation, Palo Alto, CA, USA; 2Center for Health 
Information, Chesapeake, VA, USA
Pharmaceutical agents that prevent or manage chemo-
therapy-induced toxicity (CIT) have recently become
available, and the impact of their overall healthcare cost
savings is ill defined. 
OBJECTIVE: The purpose of this review is to evaluate
the overall cost associated with CITs, particularly cardio-
vascular toxicities, hematologic toxicities, neurotoxici-
ties, and nephrotoxicities. 
METHODS: A comprehensive review of the literature was
conducted to identify studies that reported CIT-associated
costs, either as a primary or secondary study endpoint.
The diversity of this therapeutic area necessitated these ex-
clusion criteria: cancers secondary to autoimmune defi-
ciencies, chemotherapy following transplantation or radia-
tion treatment, and studies restricted to hypothetical costs
or to chemotherapy-related nausea and vomiting. Inclu-
sion criteria comprised chemically induced (or adverse
event) toxicities and cost-related measures. 
RESULTS: Definitions and methods used by researchers
measuring CIT-associated costs vary widely. Most studies
included only direct medical costs, with emphasis on inpa-
tient resource utilization. Thus, hospitalization consis-
tently was identified as the most important factor affecting
total costs, regardless of cancer type. As a percentage of to-
tal treatment costs, CIT costs comprised up to 58% of all
resources expended on inpatient cancer care. Toxicity cost
estimates ranged as follows: febrile neutropenia, $250–
$9000; cardiotoxicity, $1700–$5600; thrombocytopenia,
$1000–$2600. No study has evaluated nephrotoxicity and
neurotoxicity costs. 
CONCLUSIONS: Overall, costs associated with CITs may
be substantial. Both direct and indirect costs, costs associ-
ated with chemotherapy-induced neutropenia and nephro-
toxicity, and costs associated with ambulatory care or
with toxicities occurring beyond the initial chemotherapy
regimen need to be elucidated. A comprehensive, prospec-
tive cost-of-illness study that examines overall costs associ-
ated with CITs would help determine how to best use fi-
nite healthcare dollars to improve patient care.
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OBJECTIVE: We compared costs and outcomes associ-
ated with home and hospital-based treatment of febrile
neutropenia (FN) among pediatric oncology patients. 
METHODS: In a historical case series study we gathered
data from charts of University of New Mexico (UNM)
patients who were treated at home (n  36, 72 treat-
